Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. - Wikidata - wikimedia - TriplyDB

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

http://www.wikidata.org/entity/Q34231085

about

Customized targeted therapy in Hodgkin lymphoma: hype or hope?Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.Hodgkin's lymphoma therapy: past, present, and future.MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin Clinical targeting of the TNF and TNFR superfamilies Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Targetable molecular pathways in classical Hodgkin's lymphoma.New antibody drug treatments for lymphoma.CD30: an important new target in hematologic malignancies.Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?Brentuximab vedotin Brentuximab vedotin in Hodgkin's lymphoma.New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.CD30 as a therapeutic target for lymphoma.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Role of CD30 targeting in malignant lymphoma.An update on emerging drugs for Hodgkin lymphoma.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.Digging up the human genome: current progress in deciphering adverse drug reactions.Brentuximab Vedotin in CD30+ Lymphomas.

P2860

Q27002554-91C189DD-9EAB-47A0-8B34-A84887B36B54 Q30240160-785DF401-FB1F-4318-859F-5DE8A447B075 Q34296914-20B29DB6-0F5F-4D71-AD12-A56EC920CDA4 Q34738140-961CB68D-0E3E-44AE-BF22-1B5A3AEA3CB9 Q35669134-9B5453E1-4973-456B-AB5B-6918E19E38B7 Q36762882-D2A4E703-A200-4ACF-82FA-703A55374C0E Q37178611-DF51716F-561D-4DB0-A61D-73BA4568CA16 Q37825891-56B74F6C-D4A5-4E64-AEED-EE859AC326EB Q37852003-EDF6AE81-36A8-4A50-BC58-4ECF609665F5 Q37880873-DF85CB80-1CB9-414D-A43A-E99C54E750DB Q38016373-49552BB2-1DD9-472C-BE9D-BFC42ABD2498 Q38017578-0EFDC1B0-DE24-488E-80F0-05B5C5927D0D Q38039452-686B669D-CFD7-4E45-96C1-91DDD6F615C8 Q38085250-705727EC-A83A-4AD2-A8E7-FE6112C35247 Q38138482-DDC8D4BA-51B9-483C-AEBD-11F7F9AA84DC Q38179975-D8DFB3A7-A615-4595-B8CE-788612CDF199 Q38191191-AA522DEB-4840-42C0-8E23-67B7AD30F005 Q38205874-7E521ED9-05C7-49A4-8638-E691C64FD7BA Q38205923-83085C39-843C-4CD7-B597-E2A785B09C6B Q38340900-92316473-31EB-49C8-9BF6-47FBA4E13BD2 Q38950501-A25BA436-38E7-4186-BD47-AE230AD5D5A0 Q41108261-255EC0CB-3150-4D93-BF61-18D4584250FD Q41889353-15305FE1-C1D5-4003-A918-A0440E4931D7 Q42775414-FC3975C2-AE81-43E5-BD99-E12939FA0300

P2860

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

http://www.wikidata.org/entity/Q34231085

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@ast

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@en

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@nl

type

label

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@ast

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@en

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@nl

prefLabel

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@ast

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@en

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@nl

P1433

Q34231085-9C2224E8-3D53-420E-9426-65FAB52D8F14

P1476

Q34231085-B00145EF-329D-4605-BF4D-0640618A7770

P2093

Q34231085-0817FD27-55C1-4785-8358-B0C628D170F6

Q34231085-2C09ADBC-5DE0-4444-A564-91B531428C2A

Q34231085-4C0D25C7-9356-4FBB-8CB3-F8422718DBE3

Q34231085-7B0BFF9B-A93D-4379-ACE1-AD43A8950568

Q34231085-A4DBC054-3751-454B-8362-57B65D83648B

Q34231085-A5F41F33-1715-45FF-9463-B5E878A464C8

Q34231085-BF476AA0-0328-475C-A0F3-8DFE8A6DE59F

Q34231085-C61AD371-0D3B-4D36-B0F0-10BEFF29E74B

Q34231085-FAF52508-A333-4FBF-9A8A-7963209F9DB4

P2860

Q34231085-07832524-B73A-4BFD-83D4-589E66D6F189

Q34231085-0D0441BD-7E63-4CC7-81E2-979ED6BAB2B1

Q34231085-0E14EEF4-13E8-4B64-8255-7376F94C619C

Q34231085-12527844-493E-4986-BC79-70F1D8643F9F

Q34231085-13690C0F-5BDC-40EF-83E5-0CBEC21762C2

Q34231085-1755348E-340C-4751-BC24-3BEF8944045E

Q34231085-17FC8753-5713-4289-AA6D-2039C4C44BD9

Q34231085-23B52121-C649-4E03-8F69-0ED210FD6106

Q34231085-2DDB4BEF-17E2-42AD-B7F2-96FF8CB57769

Q34231085-2F8C5B9F-7C8D-4B54-9169-3ACA746E58F5

P304

Q34231085-E051C5A3-1664-496A-996E-6E4F8EE3D718

P31

Q34231085-F54D3BDD-67B7-4F44-84EE-F8AB565A7E05

P356

Q34231085-4FEB469D-39F8-4300-8B00-922368262C89

P433

Q34231085-A4F45314-261F-4250-9A93-58D153FE732C

P478

Q34231085-407EF71F-ACA3-4744-A6F3-5A7F8608C6BA

P50

Q34231085-D60ECE2E-193E-4D67-A36E-48FB72789912

P577

Q34231085-8FE30E00-65A3-4792-A183-B0A85DD49D78

P5875

Q34231085-28CF85E7-F7DF-4622-A605-954381A555B4

P698

Q34231085-70A1B8A0-7354-4F88-A7FF-C484F7E0B418

P932

Q34231085-31FFDBC0-93C9-4FAA-9803-845E62B04064

P356

P1433

Annals of Oncology

P1476

Serious pulmonary toxicity in ...... FcγRIIIa-158 V/F polymorphism.

@en

P2093

B D Cheson

http://www.w3.org/2001/XMLSchema#string

D M Lucas

http://www.w3.org/2001/XMLSchema#string

E D Hsi

http://www.w3.org/2001/XMLSchema#string

J C Byrd

http://www.w3.org/2001/XMLSchema#string

J L Johnson

http://www.w3.org/2001/XMLSchema#string

K A Blum

http://www.w3.org/2001/XMLSchema#string

N L Bartlett

http://www.w3.org/2001/XMLSchema#string

S-H Jung

http://www.w3.org/2001/XMLSchema#string

T S Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells

CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

CD30 prevents T-cell responses to non-lymphoid tissues.

Gemcitabine-induced pulmonary toxicity: case report and review of the literature.

A report on serious pulmonary toxicity associated with gemcitabine-based therapy.

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

From the bench to the bedside: ways to improve rituximab efficacy.

P304

2246-2254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ211

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Cancer and Leukemia Group B

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348073

http://www.w3.org/2001/XMLSchema#string

P698

20423913

http://www.w3.org/2001/XMLSchema#string

P932

2962257

http://www.w3.org/2001/XMLSchema#string